Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 12, 2024

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2023 financial results after the market close on Monday, February 12, 2024. The Company will host a conference call the following morning, Tuesday, February 13, 2024, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 41 countries as of September 30, 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103786137/en/

Investor Contact: Lauren Morris 513.579.9911 x11994 [e-mail]

Media Contact: Julie Hopkins 513.579.9911 x12627 [e-mail]